10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

EGFRVIII

Catalog # PVGS1834

Product Information

Primary Accession	NP_001333870.1
Species	Human
Sequence	Leu25-Ser378
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μg by the LAL method.
Biological Activity	Immobilized EGFRVIII[Biotin], His&Avi, Human (Cat.No.: Z03941) at 0.5 μg/ml (100 μl/Well) on streptavidin (5 μg/ml) precoated plate can bind Anti-EGFR VIII Anitibody, hFc Tag.
Expression System	HEK293
Theoretical Molecular Weight	41.6 kDa
Formulation	Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH_2O more than 100 μg/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	Epidermal growth factor receptor (EGFR) is a transmembrane protein. It can be activated by epidermal growth factor or transforming growth factor alpha (TGF-α). EGFR plays an important role in cell survival, proliferation and angiogenesis. EGFR is highly expressed in a variety of solid tumours. It is a common target for cancer therapy.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.